The effect of renal replacement therapies on serum gastrointestinal system hormones

Basit Öğe Kaydı
dc.contributor.authorBorazan, Ali
dc.contributor.authorCavdar, Zahide
dc.contributor.authorSaglam, Funda
dc.date.accessioned2024-09-18T20:11:26Z
dc.date.available2024-09-18T20:11:26Z
dc.date.issued2007
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground. The kidney is a major site for the inactivation, degradation, and clearance of a variety of peptide hormones. It has been shown that the uremia increases or decreases gastrointestinal system (GIS) hormones. Moreover, studies investigating the serum GIS hormones levels in chronic renal failure (CRF) were conducted mainly in a particular period of the renal replacement therapy, and the changes caused by continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) could not be fully demonstrated. In this study, we investigated the effect of CAPD and HD on serum GIS hormones (amylase, lipase, trypsinogen, and gastrin) levels in CRF patients who were diagnosed for the first time. Methods. Serum amylase, lipase, trypsinogen, and gastrin levels were measured in 36 patients who were just diagnosed with CRF, 22 patients with CAPD and 14 patients with HD. GIS hormones of these patients were measured before treatment and three months from the beginning of CAPD and HD treatment. As the control group, 20 normal healthy cases with well-matched age and gender were used. Results. The mean serum amylase, lipase, secretin, and gastrin levels were found meaningfully decreased according to the beginning values at third months of the CAPD and HD treatment. However, they were higher than control group. Conclusion. In patients receiving CAPD or HD as renal replacement therapy, GIS hormone levels were found to be lower, albeit higher than the healthy control group.en_US
dc.identifier.doi10.1080/08860220701643799
dc.identifier.endpage1023en_US
dc.identifier.issn0886-022X
dc.identifier.issue8en_US
dc.identifier.pmid18067050en_US
dc.identifier.scopus2-s2.0-36849064361en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1019en_US
dc.identifier.urihttps://doi.org/10.1080/08860220701643799
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8842
dc.identifier.volume29en_US
dc.identifier.wosWOS:000251448400014en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofRenal Failureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectchronic renal failureen_US
dc.subjectamilaseen_US
dc.subjectlipaseen_US
dc.subjecttrypsinogenen_US
dc.subjectgastrinen_US
dc.titleThe effect of renal replacement therapies on serum gastrointestinal system hormonesen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
47.52 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu